In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Immunologists from UNIGE have discovered the previously unsuspected anti-tumor potential of CD4 T lymphocytes. An important ...

When it is firmly attached to the CD4 receptor, HIV pulls a second, smaller receptor into its embrace. The second is usually the CCR5 receptor, which juts out of the surface of the T cell, but ...

When gp120 unites to the CD4 receptor, it must also connect to a co-receptor like CXCR4 in order to enter the cell. As a result, CXCR4 antagonists are frequently used in HIV treatment.

Again, we have to understand how HIV attaches. HIV attaches to a host cell through glycoprotein-120, as it is referred to, on the virus, and it attaches to the CD4 receptor of a host cell.

Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of glycoproteins gp41 and gp120 must bind with the CD4 receptor on the membrane of ...

The T-cell co-receptor CD4 is required for T-cell activation, and it may be involved in stabilization of the T-cell receptor and class II major histocompatibility complexes during antigen ...

The moving part is a structure called envelope glycoprotein, and AIDS researchers have been trying to figure it out for years because it is a key part of the virus’ ability to dock on a T-cell ...

Genmab granted Merck Serono worldwide rights to develop and market Humax-CD4, which is used for treatment of T-cell lymphomas, an immune system related cancer form, two years ago.

HIV-1 almost exclusively infects human blood cells –T lymphocytes, specifically– as they express the primary HIV-1 receptor known as CD4 and the preferred co-receptor CCR5. As the sequence of these ...

However, blocking activin receptor 1C on CD4+ T cells helps prevent the accumulation of immune-suppressing Tregs in tumors and slows tumor growth. We have identified a new target for anticancer ...